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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S285impacted mandibular third molar), and experienced moderate to severe
pain intensity 6 hours after surgery. Subjects received a single dose of
nano-formulated, lower dose diclofenac, indomethacin, or naproxen, an
active comparator (parent compound or celecoxib), or placebo. Safety and
tolerability were assessed by examining the treatment-emergent adverse
events (TEAE) for each treatment compared with placebo. The primary
efﬁcacy endpoints were sum of total pain relief (TOTPAR) 0 to 12 hours
(diclofenac and naproxen) and 0 to 8 hours (indomethacin.)
Results: Safety and tolerability for all nano-formulated NSAIDs and
comparator treatments, as determined by the number of subjects of 1
severe TEAE, were similar when compared with placebo. Overall, TEAEs
occurred less frequently for nano-formulated diclofenac (18 mg and 35
mg) than they did with celecoxib 400 mg. The proportion of subjects with
1 severe TEAE was 0% (0/49), 3.9% (2/51), 2.0% (1/51), and 7.8% (4/51) for
nano-formulated diclofenac 18 mg, 35 mg, celecoxib 400 mg, and placebo,
respectively. TEAEs occurred less frequently in nano-formulated indo-
methacin 20 mg and 40 mg compared with placebo. The proportion of
subjects with 1 severe TEAE was 1.0% (2/50), 1.0% (2/51), 5.9% (3/51), and
5.9% (3/51) for nano-formulated indomethacin 20 mg, 40 mg, celecoxib
400 mg, and placebo, respectively. For nano-formulated naproxen, TEAEs
occurred less frequently for both nano-formulated naproxen doses (200
mg and 400 mg) compared with placebo. The proportion of subjects with
1 severe TEAE was 2.0% (1/51), 0% (0/51), 2.0% (1/50), 2.0% (1/50), and 0%
(0/51) for nano-formulated naproxen 200 mg, 400 mg, standard naproxen
250 mg, 500 mg, and placebo, respectively.
ĂThe nano-formulated NSAIDs achieved the primary efﬁcacy endpoints by
exhibiting statistically signiﬁcant improvements (P<0.001) in TOTPAR-8 or
-12 compared with placebo. For nano-formulated diclofenac and nano-
formulated naproxen, TOTPAR values were numerically better than the
active comparators. However, these studies were not powered to assess
statistical differences.
Conclusions: Investigational, nano-formulated, lower dose, oral NSAIDs
demonstrated comparable safety and tolerability, as well as efﬁcacy, in an
established acute pain model. These Phase 2 data suggest that nano-
formulated diclofenac, indomethacin, and naproxen may offer efﬁcacy at
a lower dose and better tolerability and deserve further investigation in
Phase 3 clinical trials. The aforementioned results are in line with the FDA
directive to use the lowest effective NSAID dose.
569
BASELINE AND LONGITUDINAL PATTERNS OF NSAID USE FOR
SYMPTOMATIC KNEE OSTEOARTHRITIS: THE OAI
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5Univ. of California at San Francisco, San Francisco, CA, USAPurpose:Pharmacokinetic studies andclinical trials demonstrate that regular
use of NSAIDs are needed for its anti-inﬂammatory properties to be effective
in the treatment of knee osteoarthritis. However regular use of NSAIDs are
associatedwith increased rates of GI toxicity and cardiovascular disease. Thus
the FDA issued black box warning labels regarding these risks and suggested
that doctors and patients use NSAIDS at the lowest possible dose and
frequency to achieve clinical beneﬁt. We were interested in describing the
range of use of NSAIDs in participants with symptomatic knee osteoarthritis
and predictors of its baseline use, changes in patterns of use over time.
Methods: NSAID use was determined based upon questionnaire regarding
self-report and medication inventory requiring participants to bring in all
their prescription bottles . NSAID use was divided into three categories:
non use, OTC or infrequent use, regular use. Polytomous regression anal-
ysis was performed to predict categories of use at baseline using backward
selection models.
Results: 1172 participants with symptomatic knee OA were indentiﬁed in
the OAI study at baseline. Non use of NSAIDS was found in 722 (61.6%), 356
(30.4%) infrequent use and 94(8%) regular use. Regular users were more
likely than none users to be obese (aOR¼1.80, 95% CI 1.13-2.88), have
worse SF-12 physical function scores (aOR¼ 0.97, 95% CI 0.95-0.99), and
trends for worse WOMAC pain (aOR¼ 1.03, 95%CI 0.97-1.11, higher rates of
a history of knee surgery (aOR¼1.55, 95%CI 0.99-2.41), and concomitant
CAM therapy(aOR¼1.42,95%CI 0.90-2.23). Infrequent NSAID users
compared to non users were more likely to have worse SF-12 mental
health scores (aOR¼0.98, 0.97-0.99), worse WOMAC pain scores
(aOR¼1.05, 95%CI 1.01-1.09),and more CAM therapy use (aOR¼1.32, 95% CI
1.01-1.74). Regular users only differed from infrequent users by obesity
status (aOR¼ 1.89, 95% CI 1.16-3.09). Patterns of use are shown in the ﬁgure
below. Over 48 months of follow-up, nearly 2/3 of non users stayed non
users, while only a 1/3 of infrequent users stayed infrequent users , and
only 25% of frequent users stayed frequent users.
Conclusions: Regular NSAID use for symptomatic knee OA is modest (<
10%) in this study and is associated with obesity, worse physical func-
tioning while infrequent use is associated with worse mental health, and
more CAM therapy. Over four years of follow-up non users remained
relatively constant while infrequent and frequent users changed cate-
gories. Understanding the reasons for lack of use of NSAIDS and changing
patterns may inform better patient centered outcomes research.
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A PROPRIETARY, NANO-FORMULATED, LOWER DOSE ORAL NAPROXEN
PROVIDES EFFECTIVE PAIN RELIEF
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Purpose: Naproxen is commonly prescribed for the relief of musculo-
skeletal conditions including arthritis. Naproxen, like other NSAIDs, has
the potential for serious adverse events (AEs). NSAID AEs have demon-
strated to be dose-dependent. Our objective was to evaluate the analgesic
